AAPL343.83-3.27 (-0.94%) ▼|ABBV285.99-0.40 (-0.14%) ▼|ABT102.64-0.46 (-0.45%) ▼|ACN243.40+8.24 (+3.50%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP317.94+5.03 (+1.61%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.20+0.97 (+0.43%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.04-1.19 (-1.08%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|AAPL343.83-3.27 (-0.94%) ▼|ABBV285.99-0.40 (-0.14%) ▼|ABT102.64-0.46 (-0.45%) ▼|ACN243.40+8.24 (+3.50%) ▲|ADBE249.76+1.40 (+0.56%) ▲|AMAT416.00+20.07 (+5.07%) ▲|AMD578.44+18.18 (+3.24%) ▲|AMGN451.83+3.88 (+0.87%) ▲|AMT183.75-0.08 (-0.04%) ▼|AMZN254.60+1.50 (+0.59%) ▲|AVGO351.81+9.48 (+2.77%) ▲|AXP317.94+5.03 (+1.61%) ▲|BA167.14-1.04 (-0.62%) ▼|BAC50.85+0.17 (+0.34%) ▲|BKNG147.94-2.20 (-1.47%) ▼|BLK1,157.88+21.83 (+1.92%) ▲|BMY60.57-0.98 (-1.59%) ▼|BNY148.59+1.01 (+0.68%) ▲|BRK-B540.34-2.65 (-0.49%) ▼|C124.11+1.42 (+1.16%) ▲|CAT713.38+0.07 (+0.01%) ▲|CL91.69-0.48 (-0.52%) ▼|CMCSA21.57-0.27 (-1.24%) ▼|COF204.88+1.44 (+0.71%) ▲|COP149.06+1.10 (+0.74%) ▲|COST982.73-9.40 (-0.95%) ▼|CRM242.11+1.22 (+0.51%) ▲|CSCO110.29-1.09 (-0.98%) ▼|CVS89.95-1.18 (-1.29%) ▼|CVX229.20+0.97 (+0.43%) ▲|DE640.67+1.09 (+0.17%) ▲|DHR234.07+2.07 (+0.89%) ▲|DIS109.04-1.19 (-1.08%) ▼|DUK123.57-1.23 (-0.99%) ▼|EMR167.71+1.44 (+0.87%) ▲|FDX304.58-2.52 (-0.82%) ▼|GD354.35-0.54 (-0.15%) ▼|GE301.13+3.47 (+1.17%) ▲|GEV878.03-17.05 (-1.90%) ▼|GILD159.20+0.12 (+0.08%) ▲|GM82.48+1.94 (+2.41%) ▲|GOOG321.89+5.06 (+1.60%) ▲|GOOGL324.89+4.31 (+1.34%) ▲|GS925.17+13.40 (+1.47%) ▲|HD317.56-0.94 (-0.30%) ▼|HON219.26+0.45 (+0.21%) ▲|IBM253.22+2.97 (+1.19%) ▲|INTC95.53+1.79 (+1.91%) ▲|INTU328.19-0.26 (-0.08%) ▼|ISRG444.18-1.70 (-0.38%) ▼|JNJ271.04+2.31 (+0.86%) ▲|JPM339.30+3.51 (+1.05%) ▲|KO91.73+0.55 (+0.60%) ▲|LIN508.16-0.49 (-0.10%) ▼|LLY1,288.30+6.39 (+0.50%) ▲|LMT629.75+6.76 (+1.09%) ▲|LOW198.40+0.22 (+0.11%) ▲|LRCX253.82+12.97 (+5.39%) ▲|MA610.31+0.46 (+0.08%) ▲|MCD250.50+1.03 (+0.41%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.78+0.83 (+0.88%) ▲|META612.49-7.70 (-1.24%) ▼|MMM172.80+1.22 (+0.71%) ▲|MO72.99-0.50 (-0.68%) ▼|MRK140.93-0.89 (-0.63%) ▼|MS190.13+3.22 (+1.72%) ▲|MSFT531.01-0.32 (-0.06%) ▼|MU983.23+54.47 (+5.86%) ▲|NEE81.02-1.40 (-1.70%) ▼|NFLX61.99-0.53 (-0.85%) ▼|NKE37.15-0.41 (-1.09%) ▼|NOW150.13-4.65 (-3.00%) ▼|NVDA215.38-2.56 (-1.17%) ▼|ORCL144.54+14.01 (+10.73%) ▲|PEP132.63-0.87 (-0.65%) ▼|PFE29.45-0.35 (-1.17%) ▼|PG158.26-0.97 (-0.61%) ▼|PLTR196.81-1.92 (-0.97%) ▼|PM202.64+0.02 (+0.01%) ▲|QCOM182.97-1.20 (-0.65%) ▼|RTX195.84+1.24 (+0.64%) ▲|SBUX103.20+0.16 (+0.16%) ▲|SCHW88.76-0.54 (-0.60%) ▼|SO91.52-1.13 (-1.22%) ▼|SPG211.24-1.04 (-0.49%) ▼|T20.70-0.24 (-1.15%) ▼|TMO704.15+11.13 (+1.61%) ▲|TMUS148.08+1.25 (+0.85%) ▲|TSLA404.22-3.24 (-0.80%) ▼|TXN309.83+0.92 (+0.30%) ▲|UBER65.27-0.51 (-0.78%) ▼|UNH407.10-3.29 (-0.80%) ▼|UNP297.80-2.08 (-0.69%) ▼|UPS105.62-0.47 (-0.44%) ▼|USB59.60-0.14 (-0.23%) ▼|V400.60-1.26 (-0.31%) ▼|VZ43.18-0.75 (-1.71%) ▼|WFC83.67+1.01 (+1.22%) ▲|WMT118.77-0.55 (-0.46%) ▼|XOM182.02+2.11 (+1.17%) ▲|
11.5 C
New York
Thursday, October 29, 2026

Tag: pharmaceutical

newsFORsourcecompanycontentinformationreleases1market

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

SHANGHAI, July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering...

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging...

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq compliance follows positive upward trend in Company’s Stock Price 

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)

Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)Following this important...

Canary Speech Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity

HITRUST e1 Certification validates Canary Speech's commitment to foundational cybersecurity controls and information risk management PROVO, Utah, July 10, 2025 /PRNewswire/ -- Canary Speech, the...

AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth

AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth

Vitaquest Names Plant-based Proteins, Nootropics Among Top 2026 Supplement Trends

Plant-based proteins, nootropics among Top 2026 Dietary Supplement Trends in newly released Vitaquest report.

Varda Announces $187 million in Series C Funding to Make Medicines in Space

The El Segundo-based start-up is building infrastructure to support manufacturing in microgravity and test hypersonic reentry technologies. EL SEGUNDO, Calif., July 10, 2025 /PRNewswire/ -- Varda...

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026

Phosphorous Trichloride Market worth $3.46 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 10, 2025 /PRNewswire/ -- The report "Phosphorous Trichloride Market by Application (Plastic Additives, Agrochemicals and Pharmaceuticals, Surfactants, Flame Retardants, Oil &...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers